Profitability Recovery on Test — Can Sammaan Deliver ₹1,400 Cr FY27 PAT?
Q2 will be the critical test of management credibility after aggressive FY27 PAT and ROA guidance. Strong disbursement momentum (₹6,000 Cr in Q2, up 55% QoQ) is confirmed, but Street wants to see PAT inflection and evidence that the IHC-backed transformation is yielding profitability, not just loan growth.
The Setup
Sammaan Capital (formerly Indiabulls Housing Finance) has promised a comeback. The company reported a ₹7,598 Cr loss in FY26, but after IHC Capital invested ₹8,850 Cr for 43.5% control, management guided for ₹1,400 Cr PAT in FY27 and a 1.8% Return on Assets. Q1 FY27 delivered ₹243 Cr PAT, and October's business update showed ₹6,000 Cr disbursements in Q2—up 55% from Q1's ₹3,875 Cr. The numbers suggest momentum, but the Street wants to see sustainable profit margins, not just loan growth. Q2 results on Nov 14 will be the first real test of whether the transformation narrative holds.
What to Expect: The Key Metrics
~₹6,000 Cr
Confirmed in Oct 5 business update; 55% QoQ growth signals execution on track
~₹59,000–₹60,000 Cr
Q1 ended at ₹56,239 Cr; sequential growth ~4–5% on plan
₹300–₹500 Cr
Q1 delivered ₹243 Cr; on-track guidance requires ₹350+ Cr per quarter for ₹1,400 Cr FY27 goal
~1.6–1.8% annualized
Management targets 1.8% for FY27; validate improvement from historically negative returns
What a strong print looks like: PAT exceeds ₹350 Cr (pacing well toward ₹1,400 Cr FY27 target), asset quality remains stable (Net NPA What a weak print looks like: PAT misses expectations (below ₹300 Cr), cost-to-income ratio deteriorates, or management signals any delay in reaching the ₹1,400 Cr PAT milestone. Margin compression is the swing factor—high loan growth can hide weak profitability if yields fall faster than costs decline.
What the Street Says
Since Last Quarter: Corporate Actions & Filings
Oct 5
Q2 Business Update: ₹6,000 Cr disbursements
Validates operational momentum; guides expectations for PAT scaling
Oct 30
Warrant conversion allotment: 8.69 Cr shares to promoter Avenir at ₹139
Dilutes existing shareholders; monitoring capital structure & stake changes
Nov 4
Avenir divests 6.94% stake (8.69 Cr shares) post-allotment
Promoter reduced from ~35% to ~28% FY27 Q1; mixed signal on conviction
Sep 7 & Aug 31
NCD issuances: ₹750 Cr + ₹775 Cr in two tranches
Debt capital raising supports disbursement growth; leverage to monitor
Sep 25
NCLT admits second motion petition for amalgamation scheme
Long-term strategic consolidation; no immediate P&L impact but flag execution timeline
Routine corporate actions: Warrant allotment and follow-up divestment by promoter are procedural. Watch closely: NCD issuances imply rising leverage to fund growth. While debt capital is normal for NBFCs, a significant debt-to-equity spike or deteriorating profitability margins could signal stress. The NCLT amalgamation petition is in early stages and unlikely to be material for Q2, but if approved, could reshape the group's capital structure.
The Watch List: Three Things on Result Day
1 · PAT trajectory—is management on pace?
Q2 PAT must trend toward ₹350+ Cr to validate the ₹1,400 Cr FY27 target. Q1 delivered ₹243 Cr, implying Q2–Q4 must average ~₹386 Cr each. If Q2 comes in below ₹300 Cr or management downgrades FY27 PAT guidance, the multibagger thesis falters.
2 · Margin stability under scale
With disbursements up 55% QoQ, monitor cost-to-income ratio and net interest margin (NIM). Rapid growth can be illusory if margins compress. A widening cost ratio or NIM compression signals the PAT cannot scale with AUM growth.
3 · Asset quality—early signs of stress?
Fast origination can mask credit quality deterioration. Watch Q2 Net NPA (expect <1.5%) and any divergence in gross NPA or stage-2 asset migration. Any red flags here would derail investor confidence in the recovery thesis.
Sammaan Capital enters Q2 results with strong momentum narrative but unproven profitability. The IHC injection and 55% QoQ disbursement growth have attracted bullish analyst calls targeting ₹185–₹360 upside. However, negative ROE and modest margins mean the market is betting on a recovery, not celebrating a proven turnaround. Q2 results on Nov 14 will settle one key question: can the company translate scale into durable PAT? A credible print (₹350+ Cr PAT, stable margins, steady asset quality) validates the multibagger thesis. A miss or guidance cut likely triggers a re-rating compression back toward intrinsic value.
Informational and educational content only. Not investment advice.